TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05712785

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Use of shuotong ureteroscopy
Description: Treatment of patients with ureteral stones using the Shuotong-scopy
Study: NCT03466281

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Structured patient group education
Description: Patient education in a group setting

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Education via Internet
Description: Patient education via the internet
Study: NCT01018329

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Diffusion Tensor Imaging

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Spectroscopic Imaging

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Dynamic Contract-Enhanced magnetic resonance imaging

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Diffusion-weighted magnetic resonance imaging
Study: NCT02732795

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Morphine pharmacokinetic evaluation
Description: Each group received morphine and blood drawn to evaluate morphine PK
Study: NCT03772028

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cisplatin
Description: HIPEC with cisplatin after cytoreductive surgery
Study: NCT02529462

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: NEUROPHARMAGEN-Guided Treatment
Description: NEUROPHARMAGEN is a pharmacogenetic test developed by AB-BIOTICS S.A. that enables the specific analysis of Single-Nucleotide Polymorphisms related to the pharmacokinetics and pharmacodynamics of multiple psychoactive drugs. In this arm, psychiatrists have access to the results of the NEUROPHARMAGEN test to support their medication choices

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Treatment As Usual
Description: Clinicians treat psychiatric patients in a naturalistic way, following their routine procedures, without access to the pharmacogenetic information provided by the NEUROPHARMAGEN test
Study: NCT00479505

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: UK-369,003
Description: UK-369,003 100mg, 50mg, 25mg and 10mg doses in addition to placebo.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT01132651

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Current standard eczema treatment and standard pillow at night
Description: Subjects will continue with their current eczema care and use their normal pillow at night.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Chillow cooling pillow
Description: Subjects will use the cooling pillow to sleep on in addition to their current eczema treatment for 2 weeks.
Study: NCT03226379

Intervention type: OTHER
Group type: OTHER
Intervention: DREAMM
Description: 4 DREAMM interventions to reduce HIV-related meningoencephalitis mortality once access to essential diagnostic tests and medicines:~1. Health system strengthening~2. Delivery of a co-designed education program tailored to frontline healthcare workers~3. Implementation of an algorithm for HIV-related meningoencephalitis~4. Infectious diseases/AHD mentorship and laboratory capacity building
Study: NCT03028844

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Music therapy
Description: The musical intervention will be played for ten minutes prior to venepuncture
Study: NCT05584163

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Extracorporeal shock waves
Description: 3 times of extracorporeal shock wave therapy is performed, and 1 cycle of extracorporeal shock wave therapy is performed (every 6 weeks) every 2 cycles of chemotherapy. Echocardiography is performed at baseline and every 4 cycles of chemotherapy.
Study: NCT03851406

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: 5% Hypertonic Saline
Description: Immediately following exit from the wood smoke chamber, participants will inhale 15 mL of 5% Hypertonic Saline for 15 minutes delivered by Pari neb with a coached cough maneuver.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: 5% Hypertonic Saline
Description: Immediately following exit from the wood smoke chamber, participants will inhale 15 mL of 5% Hypertonic Saline for 15 minutes delivered by Pari neb with a coached cough maneuver.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: No treatment
Description: No inhaled treatment will be provided immediately following exit from the wood smoke chamber.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: No treatment
Description: No inhaled treatment will be provided immediately following exit from the wood smoke chamber.
Study: NCT00676520

Intervention type: DEVICE
Intervention: XIENCE V® Everolimus Eluting Coronary Stent
Description: Single-arm study designed to evaluate XIENCE V® EECSS continued safety and effectiveness during commercial use in real world settings.
Study: NCT00802997

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Sinergy
Description: radiofrequency denervation

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Placebo sham
Description: sham procedure
Study: NCT00875485

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Blood sampling
Description: Blood sampling at Years 11, 12, 13, 14, 15 and at the time of challenge dose administration and one month after challenge dose administration.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Blood sampling
Description: Blood sampling at Years 11, 12, 13, 14, 15 and at the time of challenge dose administration and one month after challenge dose administration.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Additional challenge dose
Description: If a subject became seronegative for anti-HAV antibodies (\< 15 mIU/mL) or if anti-HBs antibody concentrations decreased below 10 mIU/mL during the long-term follow-up, immune memory against the antigen was evaluated by administering a challenge dose of the appropriate antigen (vaccine) 6 to 12 months after the Year 15 follow-up time-point.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Additional challenge dose
Description: If a subject became seronegative for anti-HAV antibodies (\< 15 mIU/mL) or if anti-HBs antibody concentrations decreased below 10 mIU/mL during the long-term follow-up, immune memory against the antigen was evaluated by administering a challenge dose of the appropriate antigen (vaccine) 6 to 12 months after the Year 15 follow-up time-point.
Study: NCT02304887

Intervention type: DRUG
Intervention: Bis, SERM Teriparatide, Denosumab
Description: Osteoporotic drugs are assigned according to the disease severity, gender, age and so on.

Intervention type: DRUG
Intervention: Bis, SERM Teriparatide, Denosumab
Description: Osteoporotic drugs are assigned according to the disease severity, gender, age and so on.
Study: NCT04635943

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The placebo presentation will be an oral drop solution undistinguishable from ivermectin, but without this device pharmaceutical ingredient.
Study: NCT04381598

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: stevia rebaudiana bertoni
Description: Stevia has an anti-plaque effect because of its ability in decreasing the formation of bacterial insoluble polymers.It significantly decreases the production of TNF-R and IL-1a and slightly decreases the production of NO in stimulated cells with LPS and THP-1 showing its anti-inflammatory properties.These characteristics in combination with anti-diabetic properties could results in the effective treatment of periodontal diseases.
Study: NCT03046095

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Unilateral Resistance Exercise
Description: Unilateral Resistance exercise will include training three days per week and each session will include 3 sets of leg extension and 3 sets of leg press. In each set, the participant will complete a maximum of 12 repetitions.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Immobilization
Description: During the last two weeks of the study (week 8-10), a Don Joy adjustable knee brace will be applied to the participant's leg randomized to immobilization. The brace will be applied at a 40 degree angle relative to complete extension.
Study: NCT03397394

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rucaparib
Description: Rucaparib will be administered daily.
Study: NCT00479817

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AMG 386
Description: 10mg/kg
Study: NCT03816345

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo collection of blood, CSF, tissue, stool and urine samples

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Given IV
Study: NCT06794346

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Transdermal testosterone
Description: women will receive 300mcg of transdermal testosterone in cream daily for six months

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vaginal testosterone gel
Description: women will receive 300mcg of vaginal gel testosterone daily for six months

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Placebo group
Description: women will receive both vaginal gel and transdermal cream placebo for six months
Study: NCT06796192

Intervention type: OTHER
Intervention: Visible Light Exposure - Treated zones
Description: The treated zones were exposed to Visible Light to induce skin pigmentation (144J/cm2), 15 minutes after application.

Intervention type: OTHER
Intervention: Visible Light Exposure - Treated zones
Description: The treated zones were exposed to Visible Light to induce skin pigmentation (144J/cm2), 15 minutes after application.

Intervention type: OTHER
Intervention: Visible Light Exposure - Treated zones
Description: The treated zones were exposed to Visible Light to induce skin pigmentation (144J/cm2), 15 minutes after application.

Intervention type: OTHER
Intervention: Visible Light Exposure - Untreated zone
Description: The untreated zone was exposed to Visible Light to induce skin pigmentation (144J/cm2), as the same time as the treated zones.
Study: NCT00479817

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AMG 386
Description: 3 mg/kg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Paclitaxel 80 mg/m2 IV QW (3 on/1 off)
Study: NCT06796816

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Bioelectrical Impedance Vector Analysis (BIVA)
Description: Bioelectrical Impedance Vector Analysis (BIVA) both in total body mode (Total Body Water) and segmental mode. The device used is the BIA 101 Anniversary by Akern. The BIVA exam will be performed in total body and segmental modes.~For total body mode, the patient should be placed on a non-conductive surface. After cleansing the skin with alcohol or mild soap, 4 electrodes will be placed: 2 on the right hand (metacarpal area) and 2 on the right foot (metatarsal). The cable connected to your instrument will then be connected to the electrodes. After the instrument is switched on, the variables are read and then analysed. For segmental mode, the patient should be placed on a non-conductive surface. After cleansing the skin with alcohol or mild soap, 8 electrodes will be placed: 2 on the right hand (metacarpal area) and 2 on the left hand, 2 on the right foot (metatarsal) and 2 on the left foot.
Study: NCT00479817

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Paclitaxel 80 mg/m2 IV QW (3 on/1 off)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paclitaxel
Description: Paclitaxel 80 mg/m2 IV QW (3 on/1 off)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: AMG 386 Placebo
Description: AMG 386 Placebo
Study: NCT02414945

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Autologous tumor infiltrating lymphocytes (TILs)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Interleukin-2
Study: NCT03150745

Intervention type: PROCEDURE
Group type: OTHER
Intervention: 3- Cervical Pap smears
Description: Cervical Pap smears will be obtained using the long tip of an Ayre's spatula that will be placed in the endocervical canal with the proximal bulge resting on the ectocervix. The spatula will be carefully rotated around the cervix so that a representative sample of the whole cervix will be obtained. An additional endocervical sample will be obtained by placing a cytobrush or by the other end of the Ayer's spatula in the endocervical canal and gently rotated through 360 degrees as previously described. The samples will be then immediately plated on a slide, fixed by immersing the slide in 95% ethyl alcohol fixative for 15 to 20 minutes and stained by modified Papanicolaou stain using a hand staining procedure

Intervention type: PROCEDURE
Group type: OTHER
Intervention: 3- Cervical Pap smears
Description: Cervical Pap smears will be obtained using the long tip of an Ayre's spatula that will be placed in the endocervical canal with the proximal bulge resting on the ectocervix. The spatula will be carefully rotated around the cervix so that a representative sample of the whole cervix will be obtained. An additional endocervical sample will be obtained by placing a cytobrush or by the other end of the Ayer's spatula in the endocervical canal and gently rotated through 360 degrees as previously described. The samples will be then immediately plated on a slide, fixed by immersing the slide in 95% ethyl alcohol fixative for 15 to 20 minutes and stained by modified Papanicolaou stain using a hand staining procedure

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Colposcopic examination
Description: 0.9% saline technique to assess the cervical lesion and vasculature of the cervix, 5% acetic acid technique to determine acetowhite-positive areas. Schiller's iodine technique to visualize high glycogen containing cells. Endocervical canal assessment using (Bossman forceps or endocervical speculum or counter pressure with Q stick).~e- Biopsy using the punch biopsy forceps. Biopsy will be obtained from every abnormal colposcopic examination

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Office hysteroscopy
Description: 0.9% saline technique to assess the cervical lesion and vasculature of the cervix. 5% acetic acid technique to determine acetowhite-positive areas. Schiller's iodine technique to visualize high glycogen containing cells. Endocervical canal assessment. Endometrial cavity evaluation whenever possible. Biopsy. Biopsy will be obtained from every abnormal hysteroscopic examination.
Study: NCT04583215

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Paired Associative Stimulation (PAS)
Description: On each of the 10 days of the intervention, participants will receive PAS (or PAS-C) to the left DLPFC by delivering peripheral nerve stimulation (PNS) to the right median nerve and TMS to the left DLPFC, followed immediately by PAS (or PAS-C) to the right DLPFC by delivering PNS to the left median nerve and TMS to the right DLPFC. PAS-C differs from PAS only by including an interstimulus interval of 100 ms between PNS and TMS to the DLPFC, compared to 25 ms in the active PAS condition. Using 100 ms interval, we have previously demonstrated that PAS-C does not induce PAS-LTP in the DLPFC. If a participant cannot attend one or more of the 10 consecutive PAS or PAS-C treatment sessions, we will allow up to four extra treatment days to make up for missed sessions.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Paired Associative Stimulation (PAS)
Description: On each of the 10 days of the intervention, participants will receive PAS (or PAS-C) to the left DLPFC by delivering peripheral nerve stimulation (PNS) to the right median nerve and TMS to the left DLPFC, followed immediately by PAS (or PAS-C) to the right DLPFC by delivering PNS to the left median nerve and TMS to the right DLPFC. PAS-C differs from PAS only by including an interstimulus interval of 100 ms between PNS and TMS to the DLPFC, compared to 25 ms in the active PAS condition. Using 100 ms interval, we have previously demonstrated that PAS-C does not induce PAS-LTP in the DLPFC. If a participant cannot attend one or more of the 10 consecutive PAS or PAS-C treatment sessions, we will allow up to four extra treatment days to make up for missed sessions.
Study: NCT00682903

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: GuardianR
Description: As self monitoring of capillary glucose level is needed to validate those algorithms, we postulate that using a device able to permanently control interstitial glucose readable by both medical team and patient himself (during the session and the 5 following days after discharge) could significantly improve safety and efficiency of such educative session.
Study: NCT04601259

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Orkla Corn Plaster with salicylic acid
Description: Each participating subject will receive Orkla Corn Plasters for usage up to 28 days, or until corn resolution whichever comes first. Subjects will be instructed to change plasters daily.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Orkla Corn Protector
Description: Each participating subject will receive Orkla Corn Protector for usage up to 28 days, or until corn resolution whichever comes first. Subjects will be instructed to change plasters daily.
Study: NCT00177294

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Escitalopram
Description: Escitalopram 10 mg daily for first 6 weeks, followed by escitalopram 20 mg daily for 16 additional weeks.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Escitalopram
Description: Escitalopram 10 mg daily for first 6 weeks, followed by escitalopram 20 mg daily for 16 additional weeks.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Interpersonal Psychotherapy
Description: 16 sessions of interpersonal psychotherapy (IPT)

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Clinical Monitoring
Description: 16 weeks of depression care management(DCM). No psychotherapy will be provided.
Study: NCT03650894

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Nivolumab 240 mg IV every 2 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Description: Ipilimumab 1 mg/kg IV every 6 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bicalutamide
Description: Oral bicalutamide 150mg (3 x 50mg tablets) daily
Study: NCT03107221

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Smart Eating internet-based self-help programme
Description: An internet-based self-help programme using cognitive behavioural therapy principles to treat individuals receiving input from a specialist eating disorders service. The programme takes 3 months to complete.
Study: NCT03330054

Intervention type: DEVICE
Intervention: fundoscope
Description: Fundoscope for eye examination

Intervention type: DEVICE
Intervention: fundoscope
Description: Fundoscope for eye examination

Intervention type: DEVICE
Intervention: fundoscope
Description: Fundoscope for eye examination
Study: NCT04060212

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: prebiotic
Description: Prebiotin brand prebiotic will be consumed at 8grms/day for a period of 75 days. The prebiotic administration will begin with the second grouping of 3 fish meals.
Study: NCT00421759

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Vibrating Insoles
Description: Participants wear vibrating sandals for 3 trials of 6 minutes, during a single lab visit. The sandal vibration is on during either first or second 3 minutes of the 6 minute trial, as they walk. Also, participants wear the sandals for 2 hours while sitting, with vibrations on for one visit and off for the other.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Vibrating Insoles
Description: Participants wear vibrating sandals for 3 trials of 6 minutes, during a single lab visit. The sandal vibration is on during either first or second 3 minutes of the 6 minute trial, as they walk. Also, participants wear the sandals for 2 hours while sitting, with vibrations on for one visit and off for the other.
Study: NCT00708045

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [18F]fluoro-2-deoxy-D-glucose (FDG)
Description: Brain scan with imaging tracer to assess brain tumor metabolism
Study: NCT01803100

Intervention type: OTHER
Intervention: No intervention
Description: There is no intervention in this trial
Study: NCT06793384

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Virtual reality based Cognitive Stimulation Therapy (VR-CST)
Description: In the VR-CST condition, participants wore a head-mounted display (HMD; model: DPVR P1 Pro Headset) for the themed activities in every session except sessions 1 and 14. In these two sessions, group physical activities (such as passing a ball from one participant to another) were conducted, so no HMDs were used. In other sessions, panoramic images (e.g., wet market) and videos (e.g., the neighborhood surroundings) prepared by the project team were mainly used, supplemented by 2-dimensional images /videos in which preparing panoramic images/videos was deemed impossible. Such a situation occurred in Session 5 (current affairs), in which news clips or captions from newspaper websites served as more appropriate content for discussion than self-created panoramic images/videos.
Study: NCT03460639

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Active laser
Description: Three points on the masseter muscle (upper, middle and lower portions) and one point on the anterior temporal on each side of the face will be irradiated with a wavelength of 780 nm, radiant exposure of 134 J/cm2, power of 50 mW and irradiance of 1.675 W/cm2 for 80 seconds per point, resulting in an energy of 4 J per point and total energy of 32 J per volunteer.20,21 Point application will be performed with a conventional tip in contact with the skin (beam spot: 0.04 cm2).

Intervention type: RADIATION
Group type: SHAM_COMPARATOR
Intervention: Sham laser
Description: The same procedures will be performed in the sham group, but the device will be switched off and a recording of the emission sounds will be used to give the volunteer the auditory sensation of laser therapy.
Study: NCT06793384

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Conventional Cognitive Stimulation Therapy (Conventional CST)
Description: In the conventional CST group, 2-dimensional images/videos illustrating content identical to the VR-CST condition were displayed via tablet computers (see Table 2 for details) in which participants could manipulate the size of the image depicted or the pace of the videos with the help of the facilitator/therapy assistant.
Study: NCT03460639

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Control group
Description: In this group, we will only induce fatigue.